Outcomes | Crude analysis | p-value^^ | Odds ratio (OR) (95%CI) | p-value for adjusted analysis$** | |
---|---|---|---|---|---|
Control group | Tocilizumab group | ||||
Secondary infection (Bacterial/fungal), n (%) | 214/476 (44.9) | 132/261 (50.5) | 0.14 | 1.34 (0.91, 1.94) | 0.13 |
Resistant organisms (i.e. MDR, EDR, PDR), n (%) | 82/141(58.1) | 54/84 (64.2) | 0.36 | 1.00 (0.51, 1.98) | 0.99 |
CRE detection, n (%) | 21/476 (4.4) | 10/262 (3.8) | 0.69 | 0.67 (0.29, 1.54) | 0.34 |